BioMarin eyes FDA approval as PhIII results emerge in most common form of dwarfism
BioMarin’s drug for the most common cause of dwarfism appears to be making kids taller. The company announced topline final results from its Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
